Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.08 USD
2.93 M USD
53.40 M USD
76.01 M
About Protalix BioTherapeutics, Inc. (DE)
Sector
Industry
CEO
Dror Bashan
Website
Headquarters
Hackensack
Founded
1993
ISIN
US74365A3095
FIGI
BBG000JW08N5
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PLX is 2.06 USD — it has increased by 0.98% in the past 24 hours. Watch Protalix BioTherapeutics, Inc. (DE) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Protalix BioTherapeutics, Inc. (DE) stocks are traded under the ticker PLX.
PLX stock has risen by 10.75% compared to the previous week, the month change is a 28.75% rise, over the last year Protalix BioTherapeutics, Inc. (DE) has showed a 88.99% increase.
We've gathered analysts' opinions on Protalix BioTherapeutics, Inc. (DE) future price: according to them, PLX price has a max estimate of 15.00 USD and a min estimate of 13.00 USD. Watch PLX chart and read a more detailed Protalix BioTherapeutics, Inc. (DE) stock forecast: see what analysts think of Protalix BioTherapeutics, Inc. (DE) and suggest that you do with its stocks.
PLX stock is 4.00% volatile and has beta coefficient of 0.55. Track Protalix BioTherapeutics, Inc. (DE) stock price on the chart and check out the list of the most volatile stocks — is Protalix BioTherapeutics, Inc. (DE) there?
Today Protalix BioTherapeutics, Inc. (DE) has the market capitalization of 162.65 M, it has increased by 7.47% over the last week.
Yes, you can track Protalix BioTherapeutics, Inc. (DE) financials in yearly and quarterly reports right on TradingView.
Protalix BioTherapeutics, Inc. (DE) is going to release the next earnings report on Nov 17, 2025. Keep track of upcoming events with our Earnings Calendar.
Protalix BioTherapeutics, Inc. (DE) revenue for the last quarter amounts to 15.66 M USD, despite the estimated figure of 15.53 M USD. In the next quarter, revenue is expected to reach 17.89 M USD.
PLX net income for the last quarter is 164.00 K USD, while the quarter before that showed −3.62 M USD of net income which accounts for 104.53% change. Track more Protalix BioTherapeutics, Inc. (DE) financial stats to get the full picture.
No, PLX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 27, 2025, the company has 213 employees. See our rating of the largest employees — is Protalix BioTherapeutics, Inc. (DE) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Protalix BioTherapeutics, Inc. (DE) EBITDA is 9.60 M USD, and current EBITDA margin is 9.78%. See more stats in Protalix BioTherapeutics, Inc. (DE) financial statements.
Like other stocks, PLX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Protalix BioTherapeutics, Inc. (DE) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Protalix BioTherapeutics, Inc. (DE) technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Protalix BioTherapeutics, Inc. (DE) stock shows the buy signal. See more of Protalix BioTherapeutics, Inc. (DE) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.